Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation, announced it will extend funding for continued collaboration with Proteostasis Therapeutics, Inc., for the development of new therapies to treat the most common CF mutation, Delta F508.
Beginning this March, the CF Foundation's Patient Assistance Resource Center (PARC) will help implement a new tool for the Foundation's network of 110 cystic fibrosis care centers across the U.S. to help make it easier for care center staff to work with insurers to cover CF treatment and care.
Feb. 21, 2014
|
1 min read
The U.S. Food and Drug Administration announced today it has approved Kalydeco™ to treat people ages 6 and older who have one of eight additional cystic fibrosis mutations.
Feb. 21, 2014
|
3 min read
The Cystic Fibrosis Foundation hosted a Congressional briefing on February 11 to discuss the benefits of the Foundation's model of specialized, coordinated care and its innovative strategies for drug development, and how they can serve as an example for other rare, chronic diseases.
Feb. 12, 2014
|
3 min read